The TMPRSS2-ERG fusion promotes tumorigenesis through several mechanisms. It induces the expression of genes involved in cell invasion, migration, and angiogenesis. Additionally, the fusion disrupts normal cellular pathways, leading to unchecked cell growth and survival, and contributing to the aggressive behavior of prostate cancer.